Hypercalcemia News and Research

RSS

Hypercalcemia or increased blood level of calcium is calcium found in a concentration that is higher than the usual range of 8.5 to 10.2 mg/dL. However, this normal value may vary slightly between different laboratories due to differences in protocols.

Exploring the dual role of nirmatrelvir and bisphosphonates in COVID-19 treatment and immunity

Review examines nirmatrelvir and bisphosphonates in treating COVID-19, revealing their impact on SARS-CoV-2-specific adaptive immunity and potential to mitigate severe infections, highlighting the need for balanced long-term immunity management.

16 Nov 2023

Vitamin D supplementation reduces risk of major cardiovascular events in older adults

Research investigates the impact of vitamin D supplementation on the incidence of major cardiovascular events in older adults. It examines whether monthly doses of vitamin D can alter the occurrence of heart-related problems.

4 Jul 2023

Vitamin D supplements may reduce risk of heart attacks in people over 60

Vitamin D supplements may reduce the risk of major cardiovascular events such as heart attacks among people aged over 60, finds a clinical trial published by The BMJ today.

3 Jul 2023

Vitamin D supplements may reduce risk of heart attacks in older adults

Vitamin D supplements may reduce the risk of major cardiovascular events such as heart attacks among people aged over 60, finds a clinical trial published by The BMJ today.

28 Jun 2023

Researchers solve an 80-year-old medical mystery that causes kidney damage in children

Researchers at the University of East Anglia have solved an 80-year-old medical mystery that causes kidney damage in children and can be fatal in babies

26 Jan 2023

Experts provide first framework for treating hypercalcemia of malignancy in adults

Experts provide the first framework for treating a common and life-threatening metabolic complication of cancer known as hypercalcemia of malignancy in the Endocrine Society's new Clinical Practice Guideline.

21 Dec 2022

Bisphosphonates appear to improve COVID-19 exposure outcomes

A new retrospective study examines the effect of bisphosphonates on COVID-19 outcomes.

27 Jun 2022

ATS publishes first official clinical practice guidelines for sarcoidosis

New guidance is available for physicians who must go through a number of steps to provide a probable diagnosis of sarcoidosis - an inflammatory disease that affects the lungs, lymph glands, and other organs.

20 Apr 2020

$VITALE study: High-dose vitamin D effective in lowering fracture rates after kidney transplantation$

VITALE study: High-dose vitamin D effective in lowering fracture rates after kidney transplantation

Lead VITALE investigator Dr Marie Courbebaisse (Paris, France), commented, Our study shows that currently recommended doses of vitamin D are not sufficient to protect patients from the risk of fracture after kidney transplantation.

17 Jun 2019

Scientists develop GC-MS vitamin D test that costs as little as $0.70

Scientists have developed a rapid, sensitive and cheap test for vitamin D3 levels in blood for clinical assessment, with complete analysis costing $0.70 per sample.

11 Mar 2019

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

29 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Endocrine Society announces winners of prestigious 2019 Laureate Awards

The Endocrine Society today announced it has chosen 13 leading endocrinologists as winners of its prestigious 2019 Laureate Awards, the top honors in the field.

6 Sep 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Hospitals need to improve emergency care practices for treating older cancer patients, study reveals

A new study finds that patients with cancer, especially those aged 75 or older, are more likely to be admitted to the hospital – and less likely to be observed and released home – than patients without cancer.

25 Oct 2017

TSRI scientists develop molecular model for improving design of osteoporosis treatments

Using advanced mass spectrometry technology, scientists from the Florida campus of The Scripps Research Institute have developed a molecular model that may provide a new framework for improving the design of osteoporosis treatments.

13 Oct 2017

Surgery more effective than drug therapy in patients with tertiary hyperparathyroidism

A study led by researchers from the Nephrology group at Bellvitge Biomedical Research Institute (IDIBELL) and the University Hospital of Bellvitge (HUB), compared the results of surgery with drug therapy in patients with tertiary hyperparathyroidism, ie after a kidney transplant.

17 Dec 2015

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, announced today that Enstilar has been approved by the U.S. Food and Drug Administration for the topical treatment of plaque psoriasis in adults 18 years of age and older.

19 Oct 2015

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

3 Sep 2015